Compare Novo Nordisk A/S (NVO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Standard Lithium Ltd — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: Novo Nordisk A/S is far larger — about 420.9× Standard Lithium Ltd's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| NVO | SLI | |
|---|---|---|
Market Cap | $220.53B | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $71.70 | $5.65 |
52-Week Low | $35.29 | $2.15 |
Enterprise Value | $239.49B | $383.09M |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
